Transient monosomy 7 in a chronic myelogenous leukemia patient during nilotinib therapy: a case report

Tyrosine kinase inhibitor treated chronic myelogenous leukemia patients with monosomy 7 arising in Philadelphia chromosome negative (Ph−) cells tend to evolve into MDS/AML. However, monosomy 7 in Ph− cells can be a transient finding, and it is not an absolute indication of the emergence of a new mye...

Descripción completa

Detalles Bibliográficos
Autores principales: Jawad, Majd D., Go, Ronald S., Ketterling, Rhett P., Begna, Kebede H., Reichard, Kaaren K., Shi, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771850/
https://www.ncbi.nlm.nih.gov/pubmed/27014453
http://dx.doi.org/10.1002/ccr3.506
Descripción
Sumario:Tyrosine kinase inhibitor treated chronic myelogenous leukemia patients with monosomy 7 arising in Philadelphia chromosome negative (Ph−) cells tend to evolve into MDS/AML. However, monosomy 7 in Ph− cells can be a transient finding, and it is not an absolute indication of the emergence of a new myeloid malignancy.

Ejemplares similares